

Genetic testing for epilepsy improves patient outcomes

30 November 2022, by Olivia Dimmer



Reported Clinical Actions After a Definitive Genetic Diagnosis A, Respondents reported whether the genetic finding influenced a change in clinical management of the patient. B, Those who indicated "yes" selected all of the changes that were implemented or recommended (a patient could have >1 recommendation reported and is counted in each recommendation category). C, Those who indicated "no" reported the reason best describing why no changes were made. Credit: *JAMA Neurology* (2022). DOI: 10.1001/jamaneurol.2022.3651

Genetic testing in patients with epilepsy can inform treatment and lead to better outcomes in many cases, according to a new study published in *JAMA Neurology*.

Genetic causes are responsible for <u>seizures</u> in 30% or more of infants and toddlers and about 10% of adults with epilepsy, but <u>genetic testing</u> is not routinely done. Many insurers are hesitant to cover pricey genetic testing since there's limited research demonstrating the benefits, which is why the findings of this study are significant, said Anne Berg, Ph.D., adjunct professor of Neurology in the Division of Epilepsy and Clinical Neurophysiology and co-author of the study.

"I think a lot of us have been really frustrated that

there's this highly effective diagnostic tool out there, genetic testing, that is very much underutilized or when it is utilized, it tends to be used very late in the disease course," Berg said.

"Epilepsy is not a single disease. It's a symptom that is caused by a multitude of different diseases and a lot of these are genetic. With genetic testing, we now have that specificity in the diagnosis that can often lead to improvements in patient treatment and management. With this study, we looked at <u>patients</u> referred for genetic testing and received a positive molecular diagnosis to see if it made a difference for their care."

The study included patients referred for genetic testing between 2016 and 2020 whose testing revealed a positive molecular diagnosis. The investigators asked the patient's health care providers how the results of the panel test impacted the patient's treatment plan and outcomes.

Of the 418 patients with epilepsy and a positive diagnosis who were included in the study, both <u>children</u> and adults, nearly half saw changes in their treatment plans after genetic testing revealed new information about their condition. The most common changes included starting a new medication, referring the patient to a specialist, evaluating the patient for subclinical or extraneurological disease features, or stopping a medication. Sixteen patients were recommended for dietary therapy.

Of the half who received care informed by genetic testing, 65% reported reduction or elimination of seizures, 22% had decreases in the severity of other clinical signs, and 7% had reduced side effects from medication.

Of the half whose care was not changed following a genetic test result, the most common reason (48%) was because the patient's current management plan was already consistent with the optimal



treatment for that genetic finding. Twenty-five percent of patients had genetic test results that were not immediately informative for their treatment plan.

"The genetic testing really had an impact for these patients," Berg said. "It not only changed their treatment, but in most of those cases, it improved their outcomes. This was specifically seen with seizures, where seizures became better controlled as a result of optimizing their seizure therapy."

While more work is needed to show that early genetic testing can save health care dollars, Berg said she is encouraged by the findings of the study and hopes genetic testing can become more widespread to improve patient outcomes.

"Children can be born having seizures, and seizures in the young brain can derail normal brain development. Most of these children grow up to have profound impairments," Berg said. "But there's hope and mounting evidence that <u>early diagnosis</u> with targeted, <u>effective treatment</u> can stave off some of that disability. We are really on the cusp of a change in how we diagnose and then how we treat, and this study is an important piece of the evidence needed for genetic testing to become part of early routine diagnostic practices."

More information: Dianalee McKnight et al, Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice, *JAMA Neurology* (2022). DOI: 10.1001/jamaneurol.2022.3651

Provided by Northwestern University

APA citation: Genetic testing for epilepsy improves patient outcomes (2022, November 30) retrieved 5 December 2022 from <u>https://medicalxpress.com/news/2022-11-genetic-epilepsy-patient-outcomes.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.